Search

Your search keyword '"Sulkowski, Mark S"' showing total 906 results
Start Over Author "Sulkowski, Mark S"
906 results on '"Sulkowski, Mark S"'

2. Effects of Food Insecurity on Hepatic Steatosis and Fibrosis in People With HIV

Author

Naggie, Susanna, Diehl, Anna Mae, Kopping, Mariko, Mangus, Rebecca, Chalasani, Naga, Cheek, Kaelea, Crandall, Holly, Cummings, Oscar W., Garcia, Nicole, Gawrieh, Samer, Releford, Montreca, Vilar-Gomez, Eduardo, Sulkowski, Mark, Brinkley, Sherilyn, Coleman, Daniel, Gilman, Lee, Mekhael, Sara, Moon, Juhi, Stelmash, Lauren, Williams, Quintara, Woreta, Tinsay, Heath, Sonya L., Goepfert, Paul A., Gray, Meagan, Hogue, Olivia, Lloyd, Audrey, Logan, Heather, Spraggins, Kristen, Tingle, William, Vereen, Latasha, Loomba, Rohit, Ajmera, Veeral, Cachay, Edward, Cervantes, Vanessa, Hernandez, Christie, Madamba, Egbert, Richards, Lisa, Tesfai, Kaleb, Tincopa, Monica, Price, Jennifer, Camberos, Rosaura, Laguardia, Yesenia, Luetkemeyer, Annie, McKinney, Jeffrey, Pearlman, Brittlyn, Stern, Sophie, Lake, Jordan E., Hernandez, Marisel Negret, Somasunderam, Anoma, Sterling, Richard, Devore, Megan, Nixon, Daniel, Kardashian, Ani, Sulkowski, Mark S., Wilson, Laura A., Sterling, Richard K., Heath, Sonya, Chalasani, Naga P., and Price, Jennifer C.

Published
2024
Full Text
View/download PDF

3. Long-term open-label vebicorvir for chronic HBV infection: Safety and off-treatment responses

Author

Yuen, Man-Fung, Fung, Scott, Ma, Xiaoli, Nguyen, Tuan T., Hassanein, Tarek, Hann, Hie-Won, Elkhashab, Magdy, Nahass, Ronald G., Park, James S., Jacobson, Ira M., Ayoub, Walid S., Han, Steven-Huy, Gane, Edward J., Zomorodi, Katie, Yan, Ran, Ma, Julie, Knox, Steven J., Stamm, Luisa M., Bonacini, Maurizio, Weilert, Frank, Ramji, Alnoor, Bennett, Michael, Ravendhran, Natarajan, Chan, Sing, Dieterich, Douglas T., Kwo, Paul Yien, Schiff, Eugene R., Bae, Ho S., Lalezari, Jacob, Agarwal, Kosh, and Sulkowski, Mark S.

Published
2024
Full Text
View/download PDF

7. WED-379 Intrahepatic changes in immunologic and virologic markers during siRNA JNJ-73763989 (JNJ-3989) based treatment of chronic hepatitis B (CHB) patients: imaging mass cytometry (IMC) analyses from the INSIGHT study

Author

Thys, Kim, primary, Crabbe, Marjolein, additional, Wils, Hans, additional, Goehlmann, Hinrich, additional, Verheijden, Simon, additional, Lampertico, Pietro, additional, Asselah, Tarik, additional, Gane, Edward J., additional, Fung, Scott K., additional, Kennedy, Patrick, additional, Vanwolleghem, Thomas, additional, Janczewska, Ewa, additional, Wiesch, Julian Schulze zur, additional, Sulkowski, Mark S., additional, Guinard-Azadian, Carine, additional, Biermer, Michael, additional, and Lenz, Oliver, additional

Published
2024
Full Text
View/download PDF

8. Cardiometabolic health in people with HIV: expert consensus review

Author

Batterham, Rachel L, primary, Bedimo, Roger J, additional, Diaz, Ricardo S, additional, Guaraldi, Giovanni, additional, Lo, Janet, additional, Martínez, Esteban, additional, McComsey, Grace A, additional, Milinkovic, Ana, additional, Naito, Toshio, additional, Noe, Sebastian, additional, O’Shea, Donal, additional, Paredes, Roger, additional, Schapiro, Jonathan M, additional, Sulkowski, Mark S, additional, Venter, François, additional, Waters, Laura, additional, Yoruk, Ilksen Ungan, additional, and Young, Benjamin, additional

Published
2024
Full Text
View/download PDF

9. Safety and efficacy of vebicorvir administered with entecavir in treatment-naïve patients with chronic hepatitis B virus infection

Author

Sulkowski, Mark S., Agarwal, Kosh, Ma, Xiaoli, Nguyen, Tuan T., Schiff, Eugene R., Hann, Hie-Won L., Dieterich, Douglas T., Nahass, Ronald G., Park, James S., Chan, Sing, Han, Steven-Huy B., Gane, Edward J., Bennett, Michael, Alves, Katia, Evanchik, Marc, Yan, Ran, Huang, Qi, Lopatin, Uri, Colonno, Richard, Ma, Julie, Knox, Steven J., Stamm, Luisa M., Bonacini, Maurizio, Jacobson, Ira M., Ayoub, Walid S., Weilert, Frank, Ravendhran, Natarajan, Ramji, Alnoor, Kwo, Paul Yien, Elkhashab, Magdy, Hassanein, Tarek, Bae, Ho S., Lalezari, Jacob P., Fung, Scott K., and Yuen, Man-Fung

Published
2022
Full Text
View/download PDF

10. Safety and efficacy of vebicorvir in virologically suppressed patients with chronic hepatitis B virus infection

Author

Yuen, Man-Fung, Agarwal, Kosh, Ma, Xiaoli, Nguyen, Tuan T., Schiff, Eugene R., Hann, Hie-Won L., Dieterich, Douglas T., Nahass, Ronald G., Park, James S., Chan, Sing, Han, Steven-Huy B., Gane, Edward J., Bennett, Michael, Alves, Katia, Evanchik, Marc, Yan, Ran, Huang, Qi, Lopatin, Uri, Colonno, Richard, Ma, Julie, Knox, Steven J., Stamm, Luisa M., Bonacini, Maurizio, Jacobson, Ira M., Ayoub, Walid S., Weilert, Frank, Ravendhran, Natarajan, Ramji, Alnoor, Kwo, Paul Yien, Elkhashab, Magdy, Hassanein, Tarek, Bae, Ho S., Lalezari, Jacob P., Fung, Scott K., and Sulkowski, Mark S.

Published
2022
Full Text
View/download PDF

12. Leveraging opportunities for treatment/user simplicity (LOTUS): Navigating the current treatment landscape for achieving hepatitis C virus elimination among persons who inject drugs

Author

Sulkowski, Mark S., primary, Martinez, Anthony, additional, Tyson, Gia L., additional, Scholz, Kathleen, additional, Franco, Ricardo A., additional, Kohli, Anita, additional, Julius, Susan F., additional, Deming, Paulina, additional, Fink, Scott A., additional, Lynch, Keisa, additional, Roytman, Marina, additional, Stainbrook, Tuesdae R., additional, Turner, Marshe D., additional, Viera‐Briggs, Matthew, additional, and Ramers, Christian B., additional

Published
2024
Full Text
View/download PDF

13. Development of a long-acting direct-acting antiviral system for hepatitis C virus treatment in swine

Author

Verma, Malvika, Chu, Jacqueline N., Salam, John A. F., Faiz, Mohammed T., Eweje, Feyisope, Gwynne, Declan, Lopes, Aaron, Hess, Kaitlyn, Soares, Vance, Steiger, Christoph, McManus, Rebecca, Koeppen, Ryan, Hua, Tiffany, Hayward, Alison, Collins, Joy, Tamang, Siddartha M., Ishida, Keiko, Miller, Jonathan B., Katz, Stephanie, Slocum, Alexander H., Sulkowski, Mark S., Thomas, David L., Langer, Robert, and Traverso, Giovanni

Published
2020

14. Retrospective-prospective study of safety and efficacy of sofosbuvir-based direct-acting antivirals in HIV/HCV-coinfected participants with decompensated liver disease pre– or post–liver transplant

Author

Peters, Marion G., Kottilil, Shyam, Terrault, Norah, Amara, Dominic, Husson, Jennifer, Huprikar, Shirish, Florman, Sander, Sulkowski, Mark S., Durand, Christine M., Luetkemeyer, Anne F., Rogers, Rodney, Grab, Joshua, Haydel, Brandy, Blumberg, Emily, Dove, Lorna, Emond, Jean, Olthoff, Kim, Smith, Coleman, Fishbein, Thomas, Masur, Henry, and Stock, Peter G.

Published
2021
Full Text
View/download PDF

15. Effectiveness of Ledipasvir-Sofosbuvir Combination in Patients With Hepatitis C Virus Infection and Factors Associated With Sustained Virologic Response

Author

Terrault, Norah A, Zeuzem, Stefan, Di Bisceglie, Adrian M, Lim, Joseph K, Pockros, Paul J, Frazier, Lynn M, Kuo, Alexander, Lok, Anna S, Shiffman, Mitchell L, Ari, Ziv Ben, Akushevich, Lucy, Vainorius, Monika, Sulkowski, Mark S, Fried, Michael W, Nelson, David R, and Group, HCV-TARGET Study

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Emerging Infectious Diseases, Digestive Diseases, Hepatitis, Clinical Trials and Supportive Activities, Chronic Liver Disease and Cirrhosis, Clinical Research, Liver Disease, Infectious Diseases, Hepatitis - C, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Infection, Good Health and Well Being, Adolescent, Adult, Aged, Aged, 80 and over, Antiviral Agents, Benzimidazoles, Bilirubin, Drug Therapy, Combination, Female, Fluorenes, Genotype, Hepacivirus, Hepatitis C, Chronic, Humans, Liver Cirrhosis, Longitudinal Studies, Male, Middle Aged, Prospective Studies, Proton Pump Inhibitors, Ribavirin, Risk Factors, Serum Albumin, Sofosbuvir, Sustained Virologic Response, Time Factors, Treatment Failure, Uridine Monophosphate, Young Adult, DAA, NS5A Inhibitor, NS5B Inhibitor, Antiviral, HCV-TARGET Study Group, Neurosciences, Paediatrics and Reproductive Medicine, Gastroenterology & Hepatology, Clinical sciences, Nutrition and dietetics
Abstract

Background & aimsThe combination of ledipasvir and sofosbuvir has been approved for treatment of genotype 1 hepatitis C virus (HCV) infection, including an 8-week regimen for treatment-naïve patients without cirrhosis and a baseline level of HCV RNA

Published
2016

16. The Role of Interferon for the Treatment of Chronic Hepatitis C Virus Infection

Author

Alqahtani, Saleh A., Sulkowski, Mark S., Bernstein, Peter R., Series Editor, Garner, Amanda L., Series Editor, Georg, Gunda I., Series Editor, Kobayashi, Toshi, Series Editor, Lowe, John A., Series Editor, Meanwell, Nicholas A., Series Editor, Saxena, Anil Kumar, Series Editor, Stilz, Ulrich, Series Editor, Supuran, Claudiu T., Series Editor, Zhang, Ao, Series Editor, and Sofia, Michael J., editor

Published
2019
Full Text
View/download PDF

18. Outcomes of early vs late treatment initiation in solid organ transplantation from hepatitis C virus nucleic acid test-positive donors to hepatitis C virus-uninfected recipients: Results from the HCV-TARGET study

Author

Aleyadeh, Wesam, primary, Verna, Elizabeth C., additional, Elbeshbeshy, Hany, additional, Sulkowski, Mark S., additional, Smith, Coleman, additional, Darling, Jama, additional, Sterling, Richard K., additional, Muir, Andrew, additional, Akushevich, Lucy, additional, La, Danie, additional, Terrault, Norah, additional, Fried, Michael W., additional, and Feld, Jordan J., additional

Published
2023
Full Text
View/download PDF

19. Integrated hepatitis B virus DNA maintains surface antigen production during antiviral treatment

Author

Grudda, Tanner, Hwang, Hyon S., Taddese, Maraake, Quinn, Jeffrey, Sulkowski, Mark S., Sterling, Richard K., Balagopal, Ashwin, and Thio, Chloe L.

Subjects
DNA -- Health aspects, Antiviral agents -- Testing, Hepatitis B -- Drug therapy, Hepatitis associated antigen -- Genetic aspects, Host-virus relationships -- Genetic aspects, Health care industry
Abstract

The focus of hepatitis B functional cure, defined as sustained loss of hepatitis B virus (HBV) surface antigen (HBsAg) and HBV DNA from blood, is on eliminating or silencing the intranuclear template for HBV replication, covalently closed circular DNA (cccDNA). However, HBsAg also derives from HBV DNA integrated into the host genome (iDNA). Little is known about the contribution of iDNA to circulating HBsAg with current therapeutics. We applied a multiplex droplet digital PCR assay to demonstrate that iDNA is responsible for maintaining HBsAg quantities in some individuals. Using paired bulk liver tissue from 16 HIV/HBV-coinfected persons on nucleos(t)ide analog (NUC) therapy, we demonstrate that people with larger HBsAg declines between biopsies derive HBsAg from cccDNA, whereas people with stable HBsAg levels derive predominantly from iDNA. We applied our assay to individual hepatocytes in paired tissues from 3 people and demonstrated that the individual with significant HBsAg decline had a commensurate loss of infected cells with transcriptionally active cccDNA, while individuals without HBsAg decline had stable or increasing numbers of cells producing HBsAg from iDNA. We demonstrate that while NUC therapy may be effective at controlling cccDNA replication and transcription, innovative treatments are required to address iDNA transcription that sustains HBsAg production., Introduction For the nearly 300 million people chronically infected with hepatitis B virus (HBV), current treatments, which include pegylated interferon a (PEG-IFN-[alpha]) and nucleos(t)ide analogs (NUCs), uncommonly result in cure, [...]

Published
2022
Full Text
View/download PDF

20. Sofosbuvir and Ribavirin for Hepatitis C in Patients With HIV Coinfection

Author

Sulkowski, Mark S, Naggie, Susanna, Lalezari, Jacob, Fessel, Walford Jeffrey, Mounzer, Karam, Shuhart, Margaret, Luetkemeyer, Anne F, Asmuth, David, Gaggar, Anuj, Ni, Liyun, Svarovskaia, Evguenia, Brainard, Diana M, Symonds, William T, Subramanian, G Mani, McHutchison, John G, Rodriguez-Torres, Maribel, and Dieterich, Douglas

Subjects
Medical Microbiology, Biomedical and Clinical Sciences, Immunology, Emerging Infectious Diseases, Liver Disease, Clinical Research, Digestive Diseases, Hepatitis - C, Genetics, Clinical Trials and Supportive Activities, HIV/AIDS, Infectious Diseases, Hepatitis, Chronic Liver Disease and Cirrhosis, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Infection, Good Health and Well Being, Administration, Oral, Adult, Aged, Antiviral Agents, Coinfection, Drug Administration Schedule, Drug Therapy, Combination, Female, Genotype, HIV Infections, Hepacivirus, Hepatitis C, Humans, Male, Middle Aged, RNA, Viral, Ribavirin, Sofosbuvir, Treatment Outcome, Uridine Monophosphate, Viral Load, Young Adult, PHOTON-1 Investigators, Medical and Health Sciences, General & Internal Medicine, Biomedical and clinical sciences, Health sciences
Abstract

ImportanceTreatment of hepatitis C virus (HCV) infection in patients also infected with human immunodeficiency virus (HIV) has been limited due to drug interactions with antiretroviral therapies (ARTs) and the need to use interferon.ObjectiveTo determine the rates of HCV eradication (sustained virologic response [SVR]) and adverse events in patients with HCV-HIV coinfection receiving sofosbuvir and ribavirin treatment.Design, setting, and participantsOpen-label, nonrandomized, uncontrolled phase 3 trial conducted at 34 treatment centers in the United States and Puerto Rico (August 2012-November 2013) evaluating treatment with sofosbuvir and ribavirin among patients with HCV genotypes 1, 2, or 3 and concurrent HIV. Patients were required to be receiving ART with HIV RNA values of 50 copies/mL or less and a CD4 T-cell count of more than 200 cells/μL or to have untreated HIV infection with a CD4 T-cell count of more than 500 cells/μL. Of the treatment-naive patients, 114 had HCV genotype 1 and 68 had HCV genotype 2 or 3, and 41 treatment experienced participants who had been treated with peginterferon-ribavirin had HCV genotype 2 or 3, for a total of 223 participants.InterventionsTreatment-naive patients with HCV genotype 2 or 3 received 400 mg of sofosbuvir and weight-based ribavirin for 12 weeks and treatment-naive patients with HCV genotype 1 and treatment-experienced patients with HCV genotype 2 or 3 received the same treatment for 24 weeks.Main outcomes and measuresThe primary study outcome was the proportion of patients with SVR (serum HCV

Published
2014

21. Prevalence of steatotic liver disease, MASLD, MetALD and significant fibrosis in people with HIV in the United States.

Author

Gawrieh, Samer, Vilar‐Gomez, Eduardo, Woreta, Tinsay A., Lake, Jordan E., Wilson, Laura A., Price, Jennifer C., Naggie, Susanna, Sterling, Richard K., Heath, Sonya, Corey, Kathleen E., Cachay, Edward R., Ajmera, Veeral, Tonascia, James, Sulkowski, Mark S., Chalasani, Naga, and Loomba, Rohit

Abstract

Summary: Background: Metabolic dysfunction‐associated steatotic liver disease (MASLD) has recently been proposed as a replacement term for NAFLD. Aims: To assess the effects of this new nomenclature on the prevalence and distribution of different SLD categories in people with HIV (PWH) and identified factors associated with MASLD and clinically significant fibrosis (CSF). Methods: PWH were prospectively enrolled from 9 US centres and underwent clinical evaluation and vibration‐controlled transient elastography for controlled attenuation parameter (CAP) and liver stiffness measurement (LSM). SLD was defined as CAP ≥ 263 dB/m, CSF as LSM of ≥8 kPa, and advanced fibrosis (AF) as LSM ≥ 12 kPa. The prevalence of SLD, MASLD, metabolic dysfunction and alcohol‐associated liver disease (MetALD), ALD, cryptogenic (cSLD), CSF and AF were determined. Uni‐ and multivariate logistic regression models were used to assess factors associated with MASLD and CSF risk. Results: Of 1065 participants, 74% were male, mean (SD) age 51.6 ± 11.9 years, 46% non‐Hispanic Black and 74% with undetectable HIV RNA. The prevalence of SLD was 52%, MASLD 39%, MetALD 10%, ALD 3%, CSF 15% and AF 4%. Only 0.6% had cSLD. Black race was protective whereas obesity, ALT and AST levels were associated with increased risk of MASLD and CSF in MASLD. HIV or antiretroviral therapy did not affect MASLD risk. Conclusions: MASLD and MetALD are the dominant causes of SLD in PWH, affecting almost half. Application of the new nomenclature resulted in minimal change in the proportion of patients with MASLD who would have been diagnosed previously with NAFLD. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

26. Reply to Ozaras et al

Author

Sulkowski, Mark S., Brainard, Diana M., Yang, Jenny C., and Gane, Edward J.

Published
2017

29. Intrahepatic characterization of virological and immunological markers in two distinct populations of chronic hepatitis B: baseline assessment of core liver and fine needle aspiration biopsies from the investigational INSIGHT study

Author

Lampertico, Pietro, primary, Asselah, Tarik, additional, Gane, Edward J., additional, Fung, Scott K., additional, Kennedy, Patrick, additional, Vanwolleghem, Thomas, additional, Janczewska, Ewa, additional, zur Wiesch, Julian Schulze, additional, Sulkowski, Mark S., additional, Wils, Hans, additional, Colombo, Daniele Filippo, additional, Neto, Nadia, additional, de Troyer, Ewoud, additional, Van den Berge, Koen, additional, Göhlmann, Hinrich, additional, Aerssens, Jeroen, additional, Jerzorwski, John, additional, Anastasiou, Zacharias, additional, Lenz, Oliver, additional, Verbinnen, Thierry, additional, Kakuda, Thomas, additional, Guinard-Azadian, Carine, additional, Tuefferd, Marianne, additional, and Biermer, Michael, additional

Published
2023
Full Text
View/download PDF

30. Genetic risk factors for NAFLD and clinically significant fibrosis in persons living with HIV

Author

Gomez, Eduardo Vilar, primary, Gawrieh, Samer, additional, Liang, Tiebing, additional, Lake, Jordan, additional, Naggie, Susanna, additional, Woreta, Tinsay, additional, Price, Jennifer, additional, Sterling, Richard, additional, Heath, Sonya, additional, King, Holly, additional, Wilson, Laura, additional, Tonascia, James, additional, Bansal, Meena, additional, Corey, Kathleen, additional, Loomba, Rohit, additional, Sulkowski, Mark S., additional, and Chalasani, Naga, additional

Published
2023
Full Text
View/download PDF

31. Outcomes of early vs late treatment initiation in solid organ transplantation from HCV NAT+ donors to HCV-uninfected recipients: results from the HCV-TARGET study

Author

Aleyadeh, Wesam, primary, Verna, Elizabeth, additional, Elbeshbeshy, Hany, additional, Sulkowski, Mark S, additional, Smith, Coleman I., additional, Darling, Jama, additional, Sterling, Richard, additional, Muir, Andrew, additional, Akushevich, Lucy, additional, La, Danie, additional, Fried, Michael W., additional, and Feld, Jordan J., additional

Published
2023
Full Text
View/download PDF

32. Hepatitis B e Antigen-Negative Single Hepatocyte Analysis Shows Transcriptional Silencing and Slow Decay of Infected Cells With Treatment

Author

Thio, Chloe L, primary, Taddese, Maraake, additional, Saad, Yasmeen, additional, Zambo, Kristina, additional, Ribeiro, Ruy M, additional, Grudda, Tanner, additional, Sulkowski, Mark S, additional, Sterling, Richard K, additional, Zhang, Yang, additional, Young, Eric D, additional, Hwang, Hyon S, additional, and Balagopal, Ashwin, additional

Published
2023
Full Text
View/download PDF

37. Long-term Follow-up of Hepatitis C Patients Who Achieved Sustained Virologic Response in the Pragmatic PRIORITIZE Study

Author

Lok, Anna S., primary, Moon, Juhi, additional, Sherman, Kenneth E., additional, Khalili, Mandana, additional, Fishbein, Dawn, additional, Reddy, K. Rajender, additional, Morelli, Giuseppe, additional, Peter, Joy, additional, Nelson, David R., additional, Pearlman, Brian, additional, Michael, Larry, additional, Fried, Michael W., additional, Segal, Jodi B., additional, and Sulkowski, Mark S., additional

Published
2023
Full Text
View/download PDF

39. Faldaprevir, pegylated interferon, and ribavirin for treatment-naïve HCV genotype-1: pooled analysis of two phase 3 trials

Author

Jensen, Donald M., Asselah, Tarik, Dieterich, Douglas, Foster, Graham R., Sulkowski, Mark S., Zeuzem, Stefan, Mantry, Parvez, Yoshida, Eric M., Moreno, Christophe, Ouzan, Denis, Wright, Mark, Morano, Luis E., Buynak, Robert, Bourlière, Marc, Hassanein, Tarek, Nishiguchi, Shuhei, Kao, Jia-Horng, Omata, Masao, Paik, Seung W., Wong, David K., Tam, Edward, Kaita, Kelly, Feinman, S. Victor, Stern, Jerry O., Scherer, Joseph, Quinson, Anne-Marie, Voss, Florian, Gallivan, John-Paul, Böcher, Wulf O., and Ferenci, Peter

Published
2016
Full Text
View/download PDF

42. Evaluation of a pilot emergency department linkage to care program for patients previously diagnosed with Hepatitis C

Author

Hyde, Zak, primary, Roura, Raúl, additional, Signer, Danielle, additional, Patel, Anuj, additional, Cohen, Jacob, additional, Saheed, Mustapha, additional, Brinkley, Sherilyn, additional, Irvin, Risha, additional, Sulkowski, Mark S., additional, Thomas, David L., additional, Rothman, Richard E., additional, and Hsieh, Yu‐Hsiang, additional

Published
2022
Full Text
View/download PDF

43. Efficacy and safety of daclatasvir plus pegylated-interferon alfa 2a and ribavirin in previously untreated HCV subjects coinfected with HIV and HCV genotype-1: a Phase III, open-label study

Author

Sulkowski, Mark S., Fessel, Walford J., Lazzarin, Adriano, Berenguer, Juan, Zakharova, Natalia, Cheinquer, Hugo, Côté, Pierre, Dieterich, Douglas, Gadano, Adrian, Matthews, Gail, Molina, Jean-Michel, Moreno, Christophe, Pineda, Juan Antonio, Pulido, Federico, Rivero, Antonio, Rockstroh, Jurgen, Hernandez, Dennis, McPhee, Fiona, Eley, Timothy, Liu, Zhaohui, Mendez, Patricia, Hughes, Eric, Noviello, Stephanie, and Ackerman, Peter

Published
2017
Full Text
View/download PDF

44. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study

Author

Lawitz, Eric, Sulkowski, Mark S, Ghalib, Reem, Rodriguez-Torres, Maribel, Younossi, Zobair M, Corregidor, Ana, DeJesus, Edwin, Pearlman, Brian, Rabinovitz, Mordechai, Gitlin, Norman, Lim, Joseph K, Pockros, Paul J, Scott, John D, Fevery, Bart, Lambrecht, Tom, Ouwerkerk-Mahadevan, Sivi, Callewaert, Katleen, Symonds, William T, Picchio, Gaston, Lindsay, Karen L, Beumont, Maria, and Jacobson, Ira M

Published
2014
Full Text
View/download PDF

46. Deeper virologic suppression with the addition of vebicorvir, a first-generation hepatitis B core inhibitor, to entecavir correlates with reduced inflammation and fibrosis-4 index in treatment naïve patients with HBeAg positive chronic hepatitis B

Author

Sulkowski, Mark S, primary, Fung, Scott K, additional, Ma, Xiaoli, additional, Nguyen, Tuan T, additional, Schiff, Eugene R., additional, Hann, Hie-Won L, additional, Dieterich, Douglas T, additional, Nahass, Ronald G, additional, Park, James S, additional, Chan, Sing, additional, Han, Steven-Huy B, additional, Gane, Edward J, additional, Bennett, Michael, additional, Yan, Ran, additional, Liu, Jieming, additional, Ma, Julie, additional, Knox, Steven J, additional, Stamm, Luisa M, additional, Bonacini, Maurizio, additional, Jacobson, Ira M, additional, Ayoub, Walid S, additional, Weilert, Frank, additional, Ravendhran, Natarajan, additional, Ramji, Alnoor, additional, Kwo, Paul Yien, additional, Elkhashab, Magdy, additional, Hassanein, Tarek, additional, Bae, Ho S, additional, Lalezari, Jacob P, additional, Agarwal, Kosh, additional, and Yuen, Man-Fung, additional

Published
2022
Full Text
View/download PDF

48. Reply

Author

Saberi, Behnam, Dadabhai, Alia S., Durand, Christine M., Philosophe, Benjamin, Cameron, Andrew M., Sulkowski, Mark S., and Gurakar, Ahmet

Published
2018
Full Text
View/download PDF

50. Infections During Peginterferon/Ribavirin Therapy Are Associated With the Magnitude of Decline in Absolute Lymphocyte Count: Results of the IDEAL Study

Author

Melia, Michael T., Bräu, Norbert, Poordad, Fred, Lawitz, Eric J., Shiffman, Mitchell L., McHutchison, John G., Muir, Andrew J., Galler, Greg W., Nyberg, Lisa M., Lee, William M., Schiff, Eugene, Long, Jianmin, Noviello, Stephanie, Brass, Clifford A., Pedicone, Lisa D., and Sulkowski, Mark S.

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results